How glycobiology can help us treat and beat the COVID-19 pandemic

• Published in: The Journal of biological chemistry 2021-01, Vol.296, p.100375, Article 100375
• Main Authors: Lardone, Ricardo D., Garay, Yohana C., Parodi, Pedro, de la Fuente, Sofia, Angeloni, Genaro, Bravo, Eduardo O., Schmider, Anneke K., Irazoqui, Fernando J.
• Format: Article
• Language: English
• Subjects: COVID-19; FDA-approved drugs; glycobiology; JBC Reviews; potential therapies; SARS-CoV-2
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/j.jbc.2021.100375

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged during the last months of 2019, spreading throughout the world as a highly transmissible infectious illness designated as COVID-19. Vaccines have now appeared, but the challenges in producing sufficient material and distributing them around the world means that effective treatments to limit infection and improve recovery are still urgently needed. This review focuses on the relevance of different glycobiological molecules that could potentially serve as or inspire therapeutic tools during SARS-CoV-2 infection. As such, we highlight the glycobiology of the SARS-CoV-2 infection process, where glycans on viral proteins and on host glycosaminoglycans have critical roles in efficient infection. We also take notice of the glycan-binding proteins involved in the infective capacity of virus and in human defense. In addition, we critically evaluate the glycobiological contribution of candidate drugs for COVID-19 therapy such as glycans for vaccines, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and numerous glycosides, emphasizing some opportunities to repurpose FDA-approved drugs. For the next-generation drugs suggested here, biotechnological engineering of new probes to block the SARS-CoV-2 infection might be based on the essential glycobiological insight on glycosyltransferases, glycans, glycan-binding proteins, and glycosidases related to this pathology.